CA-NETAPP
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced that NetApp EF600 all-flash NVMe storage combined with the BeeGFS parallel file system is now certified for NVIDIA DGX SuperPOD ™. The new certification simplifies artificial intelligence (AI) and high-performance computing (HPC) infrastructure to enable faster implementation of these use cases.
Since 2018, NetApp and NVIDIA have served hundreds of customers with a range of solutions, from building AI Centers of Excellence to solving massive-scale AI training challenges. The qualification of NetApp EF600 and BeeGFS file system for DGX SuperPOD is the latest addition to a complete set of AI solutions that have been developed by the companies.
“The NetApp and NVIDIA alliance has delivered industry-leading innovation for years, and this new qualification for NVIDIA DGX SuperPOD builds on that momentum,” said Phil Brotherton, Vice President of Solutions and Alliances at NetApp. “As performance and data demands are exploding, NVIDIA DGX SuperPOD, coupled with ONTAP AI platform and DGX Foundry AI service, ensures our customers get the best-in-class model training infrastructure, with the full support of AI industry leaders.”
“Organizations modernizing their business with AI and HPC need performance, flexibility and choice as they architect their infrastructure,” said Charlie Boyle, Vice President of DGX systems at NVIDIA. “Our collaboration with NetApp enables customers building their own AI Centers of Excellence to now choose NetApp storage for their NVIDIA DGX SuperPOD, as well as use the same leading platform available as hosted infrastructure through NVIDIA DGX Foundry.”
“We’re thrilled to be working with NetApp and NVIDIA to build an HPC/AI Center of Excellence with NVIDIA DGX systems so applied learning students can experience supercomputing and high-performance computing infrastructure,” said Tonya Witherspoon, Associate Vice President, Industry Engagement & Applied Learning at Wichita State University. “NetApp is a digital fabric anchor of the innovation campus, and we can’t wait to develop the next generation of talent in this exciting space.”
Broad Portfolio of AI Infrastructure Solutions
NetApp’s portfolio of NVIDIA-accelerated solutions includes ONTAP AI to eliminate guesswork for faster adoption by using a field-proven reference architecture as well as a preconfigured, integrated solution that is easy to procure and deploy in a turnkey manner.
Also included is NVIDIA DGX Foundry , which features NVIDIA Base Command software and NetApp Keystone Flex Subscription. This combination provides a world-class hosted infrastructure solution for businesses and their data scientists who need a premium AI development experience without the struggle of building it themselves.
With today’s announcement, organizations can also build their AI Centers of Excellence leveraging the power of DGX SuperPOD on premises in combination with NetApp storage.
NetApp, in collaboration with NVIDIA, also offers tailored solutions for a variety of industries, including financial services , medicine , manufacturing , retail , higher education and government, and has sponsored and facilitated ideation workshops for customers embarking on AI journeys to accelerate success while mitigating risk.
“The AI lifecycle focus has moved up the development stack and away from the infrastructure management, driving the need for converged solutions and services that make it easier for organizations to simplify their infrastructure investments for AI use cases deployments,” said Ritu Jyoti, Group Vice President, AI/Automation Research & Advisory at IDC. “DGX SuperPOD is the latest milestone in a prolific partnership between NetApp and NVIDIA to address this need, and NetApp is well positioned to help customers solve their data management challenges regardless of where it resides.”
Additional Resources:
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom